Acute and long-term behavioral outcome of infants and children exposed in utero to either maternal depression or antidepressants: a review of the literature.
OBJECTIVE
The authors reviewed the published literature on the acute and long-term neurobehavioral effects on infants and children of either in utero exposure to maternal depression or in utero exposure to antidepressants.


METHODS
The PubMed electronic database was searched to locate 292 English-language studies from the first available year to October 2013 using the keywords pregnancy, antidepressants, depression, perinatal, and neurobehavioral.


METHODS
The authors reviewed only prospective studies that assessed the impact of maternal depression during pregnancy or maternal antidepressant treatment during pregnancy on (1) clearly defined short-term behavioral outcomes in infants (perinatal outcome) or (2) longer-term behavioral outcomes in infants and children (neurodevelopmental outcome).


METHODS
Studies were included if they were prospective and assessed the impact of maternal depression or maternal antidepressant treatment during pregnancy on clearly measurable, objective short-term and longer-term behavioral outcomes in infants and children.


RESULTS
Untreated depression during pregnancy is associated with short-term neonatal effects, including increased distress after delivery, less than optimal orientation and motor activity, and disrupted sleep. Longer-term effects on neurobehavioral outcome have also been reported, including disruptive social behavior, depression, and changes in the period of sensitivity for language discrimination. Antidepressant exposure during pregnancy is associated with adverse short-term perinatal symptomatology, including effects on autonomic and motor activity, habituation, and sleep. Longer-term studies of neurobehavioral outcomes of in utero antidepressant exposure suggest potential effects on gross motor function and language development but not cognition.


CONCLUSIONS
In utero exposure to either maternal depression or antidepressants carries risks to the developing fetus. Treatment decisions regarding whether and how to treat depression during pregnancy must be made on an individual basis, with careful consideration of the impact of these decisions on both mother and infant.
UCLA Mood Disorders Research Program, 300 Medical Plaza, Ste 1544, Los Angeles, CA 90095-7057 rsuri03@gmail.com.
Rita
R
Suri
Alex S
AS
Lin
Lee S
LS
Cohen
Lori L
LL
Altshuler
D000928:Antidepressive Agents / Q000009:adverse effects*; D002648:Child; D002652:Child Behavior / Q000187:drug effects* / Q000523:psychology; D003866:Depressive Disorder / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy* / Q000523:psychology; D011297:Prenatal Exposure Delayed Effects / Q000503:physiopathology / Q000523:psychology
D000928:Antidepressive Agents